These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

82 related items for PubMed ID: 16045031

  • 41. Serum platelet-activating factor acetylhydrolase activity: a novel potential inflammatory marker in type 1 diabetes.
    Gomes MB, Cobas RA, Nunes E, Nery M, Castro-Faria-Neto HC, Tibiriçá E.
    Prostaglandins Other Lipid Mediat; 2008 Dec; 87(1-4):42-6. PubMed ID: 18718550
    [Abstract] [Full Text] [Related]

  • 42. Levels of platelet activating factor in gingival crevice fluid following periodontal surgical therapy.
    Keles GC, Cetinkaya BO, Isildak I, Koprulu H, Acikgoz G.
    J Periodontal Res; 2006 Dec; 41(6):513-8. PubMed ID: 17076775
    [Abstract] [Full Text] [Related]

  • 43. [Observation on the expression of PS2 and platelet activating factor affected by Jianwei Yuyang granules and study its potential mechanisim against peptic ulcer].
    Huang GD, Huang YH, Li JB, Huang DF, Xiao MZ, Tang LJ, Li Q.
    Zhong Yao Cai; 2007 Dec; 30(12):1625-9. PubMed ID: 18422199
    [Abstract] [Full Text] [Related]

  • 44. Elevated serum 70 kDa heat shock protein level reflects tissue damage and disease severity in the syndrome of hemolysis, elevated liver enzymes, and low platelet count.
    Madách K, Molvarec A, Rigó J, Nagy B, Pénzes I, Karádi I, Prohászka Z.
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):133-8. PubMed ID: 18249485
    [Abstract] [Full Text] [Related]

  • 45. Platelet-activating factor (PAF) increase intracellular lipid accumulation by increasing both LDL and scavenger receptors in human mesangial cells.
    Fragopoulou E, Iatrou C, Antonopoulou S, Ruan XZ, Fernando RL, Powis SH, Moorhead JF, Varghese Z.
    J Lab Clin Med; 2006 Jun; 147(6):281-9. PubMed ID: 16750665
    [Abstract] [Full Text] [Related]

  • 46. Platelet activating factor (PAF) increases plasma protein extravasation and induces lowering of interstitial fluid pressure (P) in rat skin.
    Iversen VV, Nedrebø T, Borge BA, Salvesen GS, Reed RK.
    Acta Physiol Scand; 2005 Sep; 185(1):5-12. PubMed ID: 16128692
    [Abstract] [Full Text] [Related]

  • 47. The effects of platelet-activating factor on the secretion of interleukin-8 and growth-regulated oncogene alpha in human immortalized granulosa cell line (GC1a).
    Kawano Y, Furukawa Y, Fukuda J, Matsumoto H, Yuge A, Narahara H.
    Am J Reprod Immunol; 2007 Nov; 58(5):434-9. PubMed ID: 17922696
    [Abstract] [Full Text] [Related]

  • 48. [Platelet activating factor (PAF) and kidney failure progression].
    Camici M, Carpi A, Sagripanti A.
    Minerva Med; 1997 Sep; 88(9):329-34. PubMed ID: 9411309
    [Abstract] [Full Text] [Related]

  • 49. [Pathogenic effects of level of nitric oxide, hyponatremia and heart function on hepatorenal syndrome].
    Li GX, He Y, Luo TX, Gao BX, Nie X, Yu P, Zhang HQ.
    Zhonghua Yi Xue Za Zhi; 2011 Sep 27; 91(36):2534-7. PubMed ID: 22321879
    [Abstract] [Full Text] [Related]

  • 50. Association of arginine vasopressin receptor 1a gene polymorphisms with hepatorenal syndrome.
    Wang C, Yu Z, Luo X, Ye J, Liu S, Miu L, Bao J, Wang F.
    J Pak Med Assoc; 2017 Apr 27; 67(4):577-579. PubMed ID: 28420919
    [Abstract] [Full Text] [Related]

  • 51. [Correction of protein-energy metabolism in hepatorenal failure in surgical patients].
    Dibirov MD, Kostiuchenko MV.
    Eksp Klin Gastroenterol; 2009 Apr 27; (6):77-81. PubMed ID: 20205324
    [Abstract] [Full Text] [Related]

  • 52. Renal sodium retention in portal hypertension and hepatorenal reflex: from practice to science.
    Jiménez-Sáenz M, Soria IC, Bernardez JR, Gutierrez JM.
    Hepatology; 2003 Jun 27; 37(6):1494; author reply 1494-5. PubMed ID: 12774029
    [No Abstract] [Full Text] [Related]

  • 53. Determination of the platelet activating factor in silicotic patients and its effect on fibroblasts.
    Zhang Q, Mo Y, Lou J, Zhu X, Chen Z, He L, Zhong H.
    Environ Health Prev Med; 2001 Jan 27; 5(4):134-7. PubMed ID: 21432401
    [Abstract] [Full Text] [Related]

  • 54. PAF and human cardiovascular disorders.
    Nathan N, Denizot Y.
    J Lipid Mediat Cell Signal; 1995 Jan 27; 11(1):103-4. PubMed ID: 7728414
    [No Abstract] [Full Text] [Related]

  • 55. Dopamine and Furosemide for the Treatment of Hepatorenal Syndrome: A Reappraisal or Just Smoke and Mirrors?
    Piano S, Angeli P.
    J Clin Exp Hepatol; 2015 Dec 27; 5(4):273-5. PubMed ID: 26900267
    [No Abstract] [Full Text] [Related]

  • 56. CLINICOPATHOLOGIC Conference: hepatorenal syndrome.
    Wis Med J; 1953 Mar 27; 52(3):209-12. PubMed ID: 13039301
    [No Abstract] [Full Text] [Related]

  • 57. [Role of platelet activating factor in hepatorenal syndrome].
    Xie DS, Xie YT.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun 27; 30(3):349-51. PubMed ID: 16045031
    [Abstract] [Full Text] [Related]

  • 58. Role of platelet activating factor in development of thrombocytopenia and neutropenia in dogs with endotoxemia.
    Tsuchiya R, Kyotani K, Scott MA, Nishizono K, Ashida Y, Mochizuki T, Kitao S, Yamada T, Kobayashi K.
    Am J Vet Res; 1999 Feb 27; 60(2):216-21. PubMed ID: 10048555
    [Abstract] [Full Text] [Related]

  • 59. Outcomes for hepatorenal syndrome and acute kidney injury in patients undergoing liver transplantation: a single-center experience.
    Shusterman B, Mchedishvili G, Rosner MH.
    Transplant Proc; 2007 Jun 27; 39(5):1496-500. PubMed ID: 17580171
    [Abstract] [Full Text] [Related]

  • 60. Modifications of plasma platelet-activating factor (PAF)-acetylhydrolase/PAF system activity in patients with chronic hepatitis C virus infection.
    Caini P, Guerra CT, Giannini C, Giannelli F, Gragnani L, Petrarca A, Solazzo V, Monti M, Laffi G, Zignego AL.
    J Viral Hepat; 2007 Jan 27; 14(1):22-8. PubMed ID: 17212640
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.